Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

Pharnext S.A.. (9/5/17). "Press Release: Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference". Paris.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation Pharnext S.A. (Euronext Paris: ALPHA)
  Organisation 2 Stern Investor Relations Inc. (Stern IR)
Products Product Rodman & Renshaw Annual Global Investment Conference 2017 New York
  Product 2 Pleotherapy™ technology
Index term Index term Pharnext–Rodman & Renshaw: investor conference, 201709 supply service Pharnext presents at Rodman & Renshaw Global Investment Conference in NY
Persons Person Paoli, Xavier (Pharnext 201709 CCO)
  Person 2 Shinseki, Matthew (Stern IR 201709)

Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.

The presentation will take place as follows:
• Date: Tuesday, September 12th, 2017
• Time: 5:30 pm EDT (11:30 pm CEST)
• Venue: Lotte New York Palace Hotel in New York, New York

If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit


Xavier Paoli
Chief Commercial Officer
+33 (0)1 41 09 22 30

Investor Relations (Europe)
MC Services AG
Anne Hennecke
+49 211 529252 22

Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki
+1 212-362-1200

Financial Communication (France)
Emmanuel Huynh
+33 (0)1 44 71 20 40

Media Relations (Europe)
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64

Media Relations (U.S.)
Russo Partners
Tony Russo
Scott Santiamo
+1 212-845-4251
+1 718-344-5843

Record changed: 2017-10-29


Picture [LSA] – The Business Web Portal 650x89px

More documents for Pharnext S.A. (Euronext Paris: ALPHA)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top